Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Cancer Biopsy Market Revenue Outlook: What CAGR Is Expected Through 2030?
The market for cancer biopsies has experienced a significant upswing. Projections indicate a rise from $28.52 billion in 2025 to $32.41 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.6%. This recent expansion is underpinned by several key factors, including a rise in worldwide cancer diagnoses, the proliferation of diagnostic imaging infrastructure, the establishment of tissue biopsy as a routine diagnostic method, the expansion of pathology laboratory services, and advancements in biopsy device technology.
The global market for cancer biopsies is poised for substantial expansion in the coming years, projected to reach a valuation of $53.38 billion by 2030, driven by a compound annual growth rate of 13.3%. This notable increase over the forecast period is fueled by several key factors, including a heightened demand for precision oncology diagnostics, the escalating use of liquid biopsy tests, the broader implementation of personalized treatment strategies for cancer patients, increased investments earmarked for molecular diagnostics, and a greater emphasis on detecting cancer in its initial stages. Significant trends anticipated within this timeframe involve the wider embrace of liquid biopsy methodologies, a rise in the utilization of image-guided biopsy techniques, greater incorporation of molecular pathology testing into clinical practice, the proliferation of minimally invasive biopsy devices, and an intensified focus on identifying cancer occurrences at an early developmental phase.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19355&type=smp
Cancer Biopsy Market Growth Drivers: What Factors Are Accelerating Expansion?
The projected surge in cancer diagnoses is anticipated to be a significant catalyst for the expansion of the cancer biopsy market. Cancer, a multifaceted condition defined by uncontrolled cellular proliferation and dissemination, is becoming more widespread due to a confluence of influences including shifts in lifestyle, increased urbanization, environmental contamination, elevated rates of tobacco and alcohol use, varying degrees of healthcare accessibility, and growing public awareness. A crucial diagnostic tool, the cancer biopsy involves the removal and examination of tissue or cells from potentially malignant sites to accurately identify the cancer’s nature, stage, and extent; for illustration, the World Health Organization, an international body headquartered in Switzerland, reported in February 2024 that an estimated 35 million new cancer cases are forecasted by 2050, marking a substantial 77% rise from the approximately 20 million cases identified in 2022, thereby underscoring how the escalating incidence of cancer fuels the demand within the cancer biopsy sector.
#Cancer Biopsy Market Segment Landscape And Growth Potential
The cancer biopsy market covered in this report is segmented –
1) By Type: Tissue Biopsies, Liquid Biopsies, Other Types
2) By Application: Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Other Applications
3) By End User: Hospitals, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Tissue Biopsies: Core Needle Biopsies, Fine Needle Aspiration (FNA) Biopsies, Incisional Biopsies, Excisional Biopsies
2) By Liquid Biopsies: Circulating Tumor Cell (CTC) Analysis, Circulating Tumor DNA (ctDNA) Testing, Plasma Biomarker Testing
3) By Other Types: Bone Biopsies, Endoscopic Biopsies, Brush Biopsies, Skin Biopsies
Cancer Biopsy Market Trends: What Is Shaping Future Industry Growth?
Leading entities within the cancer biopsy sector are actively advancing liquid biopsy methodologies, aiming to facilitate unobtrusive early diagnosis and ongoing surveillance of malignancies, thereby enhancing patient prognoses and paving the way for tailored therapeutic strategies. This sophisticated, non-invasive diagnostic modality, liquid biopsy, identifies and examines genetic components derived from a blood specimen, encompassing circulating tumor DNA (ctDNA), RNA, exosomes, and a spectrum of additional indicators. As an illustration, in the month of May in the year 2023, Labcorp, an American firm renowned for its expertise in cancer biopsy production, introduced Labcorp Plasma Focus, a specialized liquid biopsy employing plasma to identify cancer-associated biomarkers. The Plasma Focus assay scrutinizes circulating cell-free DNA (cfDNA) which is shed by tumor cells into the circulatory system, enabling the construction of a comprehensive genomic profile of the patient’s tumor and pinpointing alterations within 33 genes implicated in diverse cancers like non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, and melanoma.
Cancer Biopsy Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the cancer biopsy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Roche Diagnostics GmbH, Hologic Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., Guardant Health Inc., Veracyte Inc., GRAIL Inc., Freenome Holdings Inc., Biodesix Inc., Chronix Biomedical Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Oncimmune Holdings plc, Exosome Diagnostics Inc., Epigenomics AG, Genesystems Inc., Lucence Diagnostics Pte. Ltd., ANGLE plc
Access The Complete Cancer Biopsy Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-biopsy-global-market-report
Cancer Biopsy Market Regional Analysis And Leading Geography
North Americawas the largest region in the cancer biopsy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
